argenx SE (ARGNF)
USD 697.42
(0.33%)
USD 697.42
(0.33%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.1 Billion USD | 190.7% |
| 2022 | 381.31 Million USD | 3086.52% |
| 2021 | -12.76 Million USD | 95.07% |
| 2020 | -258.8 Million EUR | -118.13% |
| 2019 | -118.64 Million EUR | -582.83% |
| 2018 | 24.57 Million EUR | -43.75% |
| 2017 | 43.68 Million EUR | 182.33% |
| 2016 | 15.47 Million EUR | 106.49% |
| 2015 | 7.49 Million EUR | 64.07% |
| 2014 | 4.56 Million EUR | 70.61% |
| 2013 | 2.67 Million EUR | 22.6% |
| 2012 | 2.18 Million EUR | 49.75% |
| 2011 | 1.45 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 777.66 Million USD | 130.53% |
| 2024 Q1 | 357.82 Million USD | 35.33% |
| 2023 Q1 | 200.8 Million USD | 24.43% |
| 2023 Q2 | 246.52 Million USD | 22.77% |
| 2023 FY | 1.1 Billion USD | 190.7% |
| 2023 Q4 | 264.41 Million USD | -10.0% |
| 2023 Q3 | 293.79 Million USD | 19.17% |
| 2022 Q4 | 161.37 Million USD | 26.35% |
| 2022 Q2 | 70.18 Million USD | 218.44% |
| 2022 Q1 | 22.04 Million USD | -15.3% |
| 2022 Q3 | 127.71 Million USD | 81.97% |
| 2022 FY | 381.31 Million USD | 3086.52% |
| 2021 FY | -12.76 Million USD | 95.07% |
| 2021 Q1 | 158.15 Million EUR | 302.03% |
| 2021 Q2 | 312.24 Million USD | 97.43% |
| 2021 Q3 | 857 Thousand USD | -99.73% |
| 2021 Q4 | 26.02 Million USD | 2936.41% |
| 2020 Q4 | -78.28 Million USD | -24.07% |
| 2020 Q3 | -63.09 Million EUR | 0.0% |
| 2020 FY | -258.8 Million EUR | -118.13% |
| 2019 FY | -118.64 Million EUR | -582.83% |
| 2019 Q1 | 40.93 Million EUR | 2779.29% |
| 2019 Q2 | 8.55 Million EUR | -79.09% |
| 2019 Q3 | 7.68 Million EUR | -10.19% |
| 2019 Q4 | -57.34 Million EUR | -846.06% |
| 2018 Q4 | 1.42 Million EUR | -41.83% |
| 2018 Q2 | 13.84 Million EUR | 101.54% |
| 2018 Q1 | 6.86 Million EUR | -33.43% |
| 2018 FY | 24.57 Million EUR | -43.75% |
| 2018 Q3 | 2.44 Million EUR | -82.34% |
| 2017 Q1 | 7.11 Million EUR | 93.52% |
| 2017 FY | 43.68 Million EUR | 182.33% |
| 2017 Q4 | 10.31 Million EUR | 34.09% |
| 2017 Q3 | 7.69 Million EUR | -58.56% |
| 2017 Q2 | 18.56 Million EUR | 160.87% |
| 2016 Q4 | 3.67 Million EUR | -33.21% |
| 2016 FY | 15.47 Million EUR | 106.49% |
| 2016 Q3 | 5.5 Million EUR | 45.64% |
| 2016 Q2 | 3.77 Million EUR | 50.51% |
| 2016 Q1 | 2.51 Million EUR | 32.96% |
| 2015 FY | 7.49 Million EUR | 64.07% |
| 2015 Q4 | 1.88 Million EUR | -26.43% |
| 2015 Q3 | 2.56 Million EUR | 48.66% |
| 2015 Q2 | 1.72 Million EUR | 31.8% |
| 2015 Q1 | 1.31 Million EUR | -26.42% |
| 2014 FY | 4.56 Million EUR | 70.61% |
| 2014 Q4 | 1.78 Million EUR | -11.35% |
| 2014 Q2 | 308.66 Thousand EUR | -9.48% |
| 2014 Q1 | 341 Thousand EUR | -63.5% |
| 2014 Q3 | 2 Million EUR | 550.83% |
| 2013 Q3 | 1.67 Million EUR | 215.1% |
| 2013 Q2 | 530.61 Thousand EUR | 21.42% |
| 2013 Q4 | 934.37 Thousand EUR | -44.12% |
| 2013 FY | 2.67 Million EUR | 22.6% |
| 2013 Q1 | 437 Thousand EUR | 0.0% |
| 2012 FY | 2.18 Million EUR | 49.75% |
| 2011 FY | 1.45 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 45448275.482% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -9369.341% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 347034.809% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | -830.655% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 4396.771% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 2297041.503% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 892230.446% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -7290.366% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -35734297.163% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -11217.96% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -1686366.955% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 3246018.009% |
| Mesoblast Limited | -35.16 Million USD | 3251.959% |
| Marizyme, Inc. | 457.7 Thousand USD | -242083.997% |
| Genus plc | 178.7 Million USD | -520.303% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | -403.617% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -1781279.166% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -270152.459% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 10077200.0% |
| ContraFect Corporation | -154 Thousand USD | 719892.857% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 2217062.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -1443967.951% |
| IMV Inc. | -962.29 Thousand USD | 115291.032% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 286158.875% |
| MultiCell Technologies, Inc. | 49.32 USD | -2247528286.05% |
| ONE Bio Corp. | 20.12 Million USD | -5407.859% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -2652.964% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -2266732.311% |
| Q BioMed Inc. | -8988.00 USD | 12332999.421% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -3823.132% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 7186828.475% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -2398.953% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 97201.278% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -1583444.286% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 22384611.309% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -788854.448% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 1136828.708% |
| GB Sciences, Inc. | -624.00 USD | 177641285.897% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 1288611.88% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 85.339% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 532923657.692% |
| Enzolytics Inc. | 30.7 Thousand USD | -3609646.646% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -229668.901% |
| MetaStat, Inc. | - USD | -Infinity% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 215544.015% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -179444.821% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | -170.656% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 12516823.126% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 1322096.685% |
| Kadimastem Ltd | -630.13 Thousand USD | 176010.832% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -112096.591% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -11433.462% |
| BioStem Technologies, Inc. | 15.42 Million USD | -7086.334% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 9366225.898% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -627721.137% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -627721.137% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -81577.539% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 3822448.276% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -246205.575% |
| SYBLEU INC | 11.69 Thousand USD | -9477336.731% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -23955.577% |
| Bioxytran, Inc. | -8285.00 USD | 13379472.36% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 297279.893% |
| Neutra Corp. | 14.33 Thousand USD | -7732589.222% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 1351906.098% |
| PureTech Health plc | -1.6 Million USD | 69250.405% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 110811.261% |
| IXICO plc | 3.27 Million USD | -33798.502% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 159823.487% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 61991.736% |
| CSL Limited | 7.7 Billion USD | 85.613% |
| Cellectis S.A. | 18 Thousand USD | -6158127.778% |